Company Of The Day: Pfizer
What?
Pfizer (NYSE:PFE) said that the third dose of its Covid-19 shot was able to neutralize the omicron variant of the novel coronavirus in lab studies. However, a two-dose regimen was much less effective at stopping the concerning new virus variant.
So What?
Relevant Articles
- What Factors Will Drive Pfizer’s Q1 Performance?
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
The findings could drive demand for booster doses of Pfizer’s shot. The U.S has already authorized boosters for all adults and it’s likely that other governments could also follow suit.
See Our Complete Analysis For Pfizer
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates